Vera Therapeutics stock sinks following competitor’s successful trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street futures fall as oil, Treasury yields rise on Iran tensions
- Oil prices fall after hitting over one-month high; traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- Berkshire’s Abel says data centers are energy opportunity
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
JPMorgan Defending Vera Therapeutics (VERA): 'pre-market weakness is overdone'
June 6, 2025 9:45 AM EDTJPMorgan analyst Anupam Rama reiterated an Overweight rating and $68.00 price target on Vera Therapeutics (NASDAQ: VERA).
The analyst comments "We view the downside in VERA shares pre-market as overdone given: 1) the totality of VERAs own phase 3 data for atacicept presented earlier this week (which was very solid), 2) our view that profiles of atacicept / sibeprenlimab are likely more similar than different on the clinical side (key considerations... More
Raymond James on Vera Therapeutics (VERA): 'we don’t think this is a referendum on the overall efficacy of these drugs in IgAN'
June 6, 2025 8:43 AM EDTRaymond James analyst Ryan Deschner reiterated a Strong Buy rating and $73.00 price target on Vera Therapeutics (NASDAQ: VERA).
The analyst comments "Otsuka reported a 51.2% placebo-adjusted proteinuria reduction for its Phase 3 VISIONARY study in IgAN at ERA today. While this result is numerically higher than what VERA reported earlier... More
Guggenheim on Vera Therapeutics (VERA): 'we would be incremental buyers on any weakness'
June 6, 2025 8:17 AM EDTGuggenheim analyst Vamil Divan reiterated a Buy rating and $65.00 price target on Vera Therapeutics (NASDAQ: VERA).
The analyst comments "Otsuka's (4578-JP) sibeprenlimab Phase 3 data presented at ERA this morning demonstrated impressive 51.2% placebo-adjusted proteinuria reduction in IgAN, numerically exceeding atacicept's 42% result, but we believe the competitive positioning remains more nuanced than headline efficacy numbers suggest. While sibeprenlimab's efficacy represents the strongest numerical result reported to date in IgAN Phase 3 trials, the... More
TD Cowen Reiterates Buy Rating on Vera Therapeutics (VERA)
June 6, 2025 8:15 AM EDTTD Cowen analyst Ritu Baral reiterated a Buy rating and $60.00 price target on Vera Therapeutics (NASDAQ: VERA).
The analyst comments "The News: This morning at ERA, IgAN competitor Otsuka presented late breaking 36wk data from their ongoing Ph3 APRIL-only-inhibitor sibeprenlimab trial in IgAN. Data showed LSM 51.2% UPCR reduction (-50.2% sibe' vs +2.1% PBO). Safety was overall benign, with sibe' well tolerated. Injection site pain was slightly higher in the tx arm (13.2% vs 10.7% PBO), likely due to large injection volume. The presenter called out the imbalance of COVID-19 infections (12.5% vs 7.1% PBO), although argued no... More
Evercore ISI Reiterates Outperform Rating on Vera Therapeutics (VERA)
June 6, 2025 8:14 AM EDTEvercore ISI analyst Liisa Bayko reiterated an Outperform rating and $75.00 price target on Vera Therapeutics (NASDAQ: VERA)
The analyst comments "LIVE FROM VIENNA SLIDES INSIDE + live KOL event Our key takeaway? There are two good B cell modulators for patients. Details Early this... More
